Lakewood-Amedex Inc   Report issue

For profit Phase 2
Founded: Florida New York United States (2006)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2016
NCT02737722
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Lakewood-Amedex Inc

Active Ingredients

Drugs in Phase 2 Trials (1)

bisphosphocin nu-3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetic Foot (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1